3 minute read
Oct. 6, 2023

Welcome to Phase III!

drughunter.com
Drug Hunter Team

With initial signs of efficacy and tolerability, Phase III of Drug Hunter is here! To address your helpful feedback, we’ve rebuilt the platform from scratch to support new features and enhancements. We appreciate your patience with the rollout - if you spot any issues, please let us know here!

Show Me the Molecules!

With thousands of articles now, many of you have mentioned wanting to see more examples from previous coverage. Now, every time you visit the homepage, the left panel will show you a new industry example that you can click on to learn more about.

Faster Browsing

At Drug Hunter, we love structures so much that we forgot to include basic things like headlines and abstracts. Oops! From now on, every new case study will have an actual descriptive title and caption to help our friends beyond chemistry decide what to read. Check out the "Latest" page by clicking "Latest" on the top left to skim through multiple stories at at time quickly.

Check out the latest articles by clicking "Latest" on the top left to skim through multiple stories at at time quickly.

Super Search

A common complaint about this version of the site was the difficulty in searching for articles. We’ve completely overhauled how this works, and the new platform’s dynamic search is much faster and more intuitive, to make it easier to find targets, modalities, mechanisms, and problems (e.g. “CYP induction”). Press Command-K on Mac, or Control-K on PC, to pull up the search, or click the search bar at the top right to activate it.

Clicking “SEE MORE RESULTS” will show you why these search results are being recommended, highlighting keywords in-line, will allow you to filter by category, and see more results.

Structure Search

The structure search is being updated to be significantly faster, so you can look for industry examples of unusual functional groups being used (alkynes, azetidines, …) or find that one wacky molecule you remember from two years ago but can’t remember the name of (it’s always “compound 12”).

The structure search page, which you can play around with here.

Smoother Logins and Single Sign-on

To log in to your Premium account, click "Sign In" at the top right. If you don't already have the account set up, check in with your team administrator or reach out to us at drughunter.com/contact.

One of the most common issues reported was the login system. We had to completely tear this one out and rebuild it, but you should now be able to stay logged in for longer and sign-in directly to pages you’re trying to read. Single sign-on through identity providers like Okta, Google Workspace, or Microsoft Azure are now also supported for Enterprise plans, and we’ve already been in touch with many of your administrators to support this ahead of time.

Passwordless, Mobile-Based Login

While it’ll take some time to roll out a mobile app, in the meantime, logins are now passwordless, only requiring an e-mailed or texted code. So you can delete your stored “Drughunter123!” password and have an easier time reading about the latest molecule on the train.

Share Your Feedback!

If you already have a Drug Hunter Premium account, you and your plan administrator should have heard from Melissa, Joe, or Nicole via e-mail with instructions to log into the new platform. If you haven’t seen anything, check your spam, or contact us and we’ll get you set up.

We’re most excited about this new platform because it will give us the flexibility to continue adding features, improving experience, and adding new content. If you encounter any issues, don’t leave us with non-monitorable tox! Tell us what you want to see improved at drughunter.com/contact and someone from our team will get back to you as soon as we can.

Join Drug Hunter to access scientifically rich molecule case studies, patent highlights, and structure search to spark research ideas in minutes. Get in touch by filling out the form below and a Drug Team member will be in touch with you and your team shortly.
Loading...

twitterlinkedinemail

Other articles you may be interested in